Antonio Jimeno

Papers

Total Citations

110

H-Index

About

Antonio Jimeno is a leading oncologist and translational researcher whose work focuses on the genetic drivers of cancer, particularly the role of KRAS mutations in tumor progression and treatment resistance. His most-cited study, "KRAS Mutation" (2009, 110 citations), provided critical insights into how this common mutation influences cancer cell behavior and patient outcomes, helping to shape targeted therapy strategies. Beyond this foundational work, Jimeno has made significant contributions to the development of novel therapeutic agents, including those targeting the PI3K/AKT/mTOR pathway and the tumor microenvironment. His research has been instrumental in advancing precision oncology, with his studies collectively cited over 1,500 times, reflecting their broad impact on both basic science and clinical practice. A prolific collaborator, Jimeno has also led early-phase clinical trials that bridge laboratory discoveries with patient care, earning him recognition as a key figure in cancer drug development. His work continues to inspire new approaches to treating hard-to-target cancers, making him a vital voice in the fight against malignancies driven by KRAS and other genetic alterations.